- Home
- CBRE vs TOVX Comparison
CBRE vs TOVX Comparison
Compare CBRE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | TOVX |
|---|---|---|
| Founded | 1906 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7B | 7.3M |
| IPO Year | 2004 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CBRE | TOVX |
|---|---|---|
| Price | $168.72 | $0.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $177.25 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 10.7M |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.63 | N/A |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $39,325,000,000.00 | N/A |
| Revenue This Year | $16.26 | N/A |
| Revenue Next Year | $9.61 | N/A |
| P/E Ratio | $41.03 | ★ N/A |
| Revenue Growth | ★ 14.61 | N/A |
| 52 Week Low | $108.45 | $0.17 |
| 52 Week High | $171.00 | $2.03 |
Technical Indicators
Market Signals| Indicator | CBRE | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 50.13 |
| Support Level | $159.23 | $0.19 |
| Resistance Level | $165.71 | $0.26 |
| Average True Range (ATR) | 2.67 | 0.03 |
| MACD | 0.39 | 0.01 |
| Stochastic Oscillator | 95.21 | 62.05 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.